Compare Wockhardt with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs PROCTER & GAMBLE HEALTH - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT PROCTER & GAMBLE HEALTH WOCKHARDT/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x -20.0 52.4 - View Chart
P/BV x 1.1 4.7 22.2% View Chart
Dividend Yield % 0.0 10.0 0.0%  

Financials

 WOCKHARDT   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
WOCKHARDT/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1,0123,549 28.5%   
Low Rs5321,301 40.8%   
Sales per share (Unadj.) Rs355.9511.4 69.6%  
Earnings per share (Unadj.) Rs-60.361.3 -98.3%  
Cash flow per share (Unadj.) Rs-46.874.0 -63.2%  
Dividends per share (Unadj.) Rs0.01440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs257.8927.8 27.8%  
Shares outstanding (eoy) m110.6316.60 666.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.24.7 45.7%   
Avg P/E ratio x-12.839.6 -32.4%  
P/CF ratio (eoy) x-16.532.8 -50.4%  
Price / Book Value ratio x3.02.6 114.5%  
Dividend payout %0717.9 -0.0%   
Avg Mkt Cap Rs m85,37940,257 212.1%   
No. of employees `0006.31.1 551.5%   
Total wages/salary Rs m9,3711,313 713.8%   
Avg. sales/employee Rs Th6,295.07,486.7 84.1%   
Avg. wages/employee Rs Th1,498.31,157.6 129.4%   
Avg. net profit/employee Rs Th-1,066.3897.2 -118.8%   
INCOME DATA
Net Sales Rs m39,3698,490 463.7%  
Other income Rs m1,202244 492.9%   
Total revenues Rs m40,5718,734 464.5%   
Gross profit Rs m181,482 1.2%  
Depreciation Rs m1,495211 708.0%   
Interest Rs m2,5550-   
Profit before tax Rs m-2,8301,514 -186.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,58266 -5,460.2%   
Tax Rs m257563 45.7%   
Profit after tax Rs m-6,6691,017 -655.4%  
Gross profit margin %017.5 0.3%  
Effective tax rate %-9.137.1 -24.5%   
Net profit margin %-16.912.0 -141.3%  
BALANCE SHEET DATA
Current assets Rs m33,79615,343 220.3%   
Current liabilities Rs m26,9171,960 1,373.2%   
Net working cap to sales %17.5157.6 11.1%  
Current ratio x1.37.8 16.0%  
Inventory Days Days7949 162.8%  
Debtors Days Days8928 313.7%  
Net fixed assets Rs m39,6641,209 3,279.9%   
Share capital Rs m553166 333.3%   
"Free" reserves Rs m27,96815,235 183.6%   
Net worth Rs m28,52215,401 185.2%   
Long term debt Rs m21,7310-   
Total assets Rs m81,62017,595 463.9%  
Interest coverage x-0.1NM-  
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.5 100.0%   
Return on assets %-5.05.8 -87.2%  
Return on equity %-23.46.6 -353.9%  
Return on capital %-7.710.3 -74.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,8071,636 599.3%   
Fx outflow Rs m1,7894,368 40.9%   
Net fx Rs m8,019-2,732 -293.5%   
CASH FLOW
From Operations Rs m684-1,304 -52.5%  
From Investments Rs m6,30212,697 49.6%  
From Financial Activity Rs m-7,695-301 2,560.6%  
Net Cashflow Rs m-66411,093 -6.0%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 2.3 18.2 12.6%  
FIIs % 7.7 1.0 770.0%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 29.1 52.9%  
Shareholders   67,757 28,591 237.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  PANACEA BIOTECH  

Compare WOCKHARDT With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

September Quarter Results, IPO Buzz, and Top Stocks in Action Today(Pre-Open)

On Wednesday, Indian share markets traded rangebound throughout the day and ended marginally higher. The BSE Sensex closed higher by 95 points to end above 39,000-mark.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

My Top 10 Stocks for Accelerated Profits

Oct 18, 2019

Equitymaster's co-head of research and editor of Microcap Millionaires, Rahul Shah, talks to us about his market-beating system and his 10 best stocks to buy now. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Oct 24, 2019 09:35 AM

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - ELDER PHARMA COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS